Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
22 June, 2026
Novel lung cancer radiation therapy approach to be tested in new PRIME-Lung trial
LATEST NEWS: 22 June 2026 In an important step
17 June, 2026
TROG Facility Alliance Member in Focus: Radiation Oncology Network, Western Sydney Local Health District
TROG’s Facility Alliance Members (FAM) are the cornerstone of